BcII-8

........10........20........30........40........50........60........70........80........90.......100.......110.......120.......130.......140.......150.......160.......170.......180.......190.......200.......210.......220.......230.......240.......250......... MKKKMMLKVGLCVSLLGVSQFASAAFPAQAAEKVEQKIIKNQEGAISISQLNSHVWVHTEMVYFNGEAVPSNGLVLNTSKGIVLIDSSWDDKLTKELIEKIEKKFHKPITDAIITHAHVDRIGGIKTLKEKGIQVHSTALTATLAKKNGYEEPIADLKDMTNMKFGNIKVETFYPGKGHTEDNITVWLPQYKILFGGCLVKSTDAKDLGNVVDAFVDVWVGSVGNVMSRYRNIKSVVPGHGKVGDKSLLSHTLDLLQAK

BcII-45	............................................T.............................I........................M..........................................K................I...................................................A.......A.......N.............E..............E..	96.14 %
BcII-54	.Q....I................E....................T.............................I......L.................M....L......................................................I...................................................A.......A...E...N.............EA..............S.	93.82 %

Last updated: May 02, 2025.

If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.

The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).

Contact: contact@bldb.eu

Live statistics (since March 29th, 2025)